CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
多发性骨髓瘤 CAR-T 细胞可及性改善但仍有限
英文原题：CAR T-cell Availability for Multiple Myeloma Improving but Still Limited.
查看英文原题
CAR T-cell Availability for Multiple Myeloma Improving but Still Limited.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
2022年的一项调查发现，等待接受CAR-T 细胞治疗的多发性骨髓瘤患者中，仅约25%最终接受了治疗。病毒载体短缺等生产瓶颈限制了供应。新的细胞生产和检测方法或可改善治疗可及性；但若CAR-T 获批用于治疗流程中更早阶段，需求也可能大幅上升。
展开英文摘要原文
A 2022 survey found that only about 25% of patients with multiple myeloma who were waiting for CAR T-cell therapy received the treatment. Manufacturing bottlenecks, such as shortages of viral vectors, limited supply. New approaches for manufacturing and testing the cells could improve their availability, but demand could also soar if they are approved for earlier use in treatment regimens.
论文信息
- 期刊
- Cancer discovery2023 Dec 12
- 原文标识
- PubMed 37819046 · DOI 10.1158/2159-8290.CD-ND2023-0009